GEN Exclusives

More »

GEN News Highlights

More »
Jun 9, 2010

Eisai Gains U.S. Commercialization Rights to Helsinn’s Combination Antiemetic

  • Eisai negotiated U.S. co-promotion rights to Helsinn Healthcare’s Phase III drug candidate for the prevention of chemotherapy-induced nausea and vomiting. The drug is an oral- and IV-formulated, fixed-dose combination of the neurokinin-1 receptor antagonist, netupitant, and the serotonin-3 (5-HT3) receptor antagonist, palonosetron.

    Helsinn will be responsible for carrying out all development and regulatory activities. If approved by FDA, the new products will be co-promoted in the U.S. by Eisai. Helsinn’s manufacturing affiliate in Ireland, Helsinn Birex Pharmaceuticals, will manufacture and supply the finished product for clinical and commercial use in the U.S.

    Eisai and Helsinn also signed a detail service agreement to co-promote the existing palonosetron drug, Aloxi®, in the U.S. Helsinn says that it will recruit and hire a dedicated sales force.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?